Cost-Effectiveness Analysis of Antiviral Therapies for Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients in China

Clinical Drug Investigation

Volumn 35, Issue 3, 2015, Pages 197-209

  Zhang, Chi ^a   Ke, Weixia ^a   Gao, Yanhui ^a   Zhou, Shudong ^a   Liu, Li ^a   Ye, Xiaohua ^a   Yao, Zhenjiang ^a   Yang, Yi ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE; TELBIVUDINE; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN;

ANTIVIRAL THERAPY; ARTICLE; CHINA; CHRONIC HEPATITIS B; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; ADULT; COST BENEFIT ANALYSIS; ECONOMICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; METABOLISM; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CHINA; COST-BENEFIT ANALYSIS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS;

EID: 84925519869     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-015-0273-y     Document Type: Article

References (53)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486–500.
2. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J Epidemiol. 2011;32(4):405–15.
3. Cheng J. The diagnosis and treatments for HBeAg-negative chronic hepatitis B patients should be full attention. Chin J Infect Dis. 2006;24:1–2.
4. Wei L, Hu SL, Hou JL, Liu GG, Ren H, Duan ZP, et al. A novel estimation of the impact of treatment with entecavir on long-term mortality, morbidity, and health care costs of chronic hepatitis B in China. Value Health Reg Issue. 2013;2:48–56.
5. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72–84.
6. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.
7. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–7.
8. Zeng MD, Mao YM, Yao GB, Hou JL, Wang H, Ren H, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int. 2012;32(1):137–46.
9. Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009;10(2):131–7.
10. Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF, et al. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol. 2011;55(3):522–8.
11. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.
12. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.
13. Liaw YF, Kao JH, Priatvisuth T, Chan LY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263–83.
14. Wu B, Li T, Chen HF, Shen JF. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010;13(5):592–600.
15. China Guidelines for Pharmacoeconomic Evaluations. China J Pharm Econ. 2010;5:5–43.
16. Yao GB, Cui ZY, Yao JL, Zhang DF, Ji NX, Huang Y. Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study. Chin J Hepatol. 2003;11(2):103–8.
17. Li KJ, Lou XZ, Xia H, Zhao Y, Wang W, Na Y, et al. A clinical study of home-made adefovir dipivoxil in the 48-weeks treatment of patients with HBeAg-positive chronic hepatitis B. Modern Prev Med. 2010;17:3386–7.
18. Wang HY, Guo RC. Comparative study on the domestic and imported entecavir. J Pharm Res. 2014;33:100–2.
19. He J, Bowen JM, Xie F, Goeree R. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. Value Health. 2012;15(6):894–906.
20. National Bureau of Statistics of China. National Data. 2013. http://data.stats.gov.cn/workspace/index?m=hgnd. Accessed Sep 2014.
21. Huang J, Chen XP, Chen XF, Chen WL, Chen R, Ma XJ, et al. Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients. Chin J Hepatol. 2011;19(3):178–81.
22. Huang H, Zhu CW, Yu XF, Wang GS, Wang JY. The development of cirrhosis in Chinese patients with chronic hepatitis B. Hepatol Int. 2007;06:437–40.
23. Xu B, Hu DC, Rosenberg DM, Jiang QW, Lin XM, Lu JL, et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol. 2003;18(12):1345–52.
24. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35(6):1522–7.
25. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1(1):267–73.
26. Hui AY, Chan HL, Leung NW, Huang LC, Chan FK, Sung JJ. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol. 2002;34(5):569–72.
27. Wang SB, Wang JH, Chen J, Giri RK, Chen MH. Natural history of liver cirrhosis in south China based on a large cohort study in one center: a follow-up study for up to 5 years in 920 patients. Chin Med J (Engl). 2012;125(12):2157–62.
28. Lo CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2004;10(3):440–7.
29. Wu TJ, Chan KM, Chou HS, Lee CF, Wu TH, Chen TC, et al. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. Ann Surg Oncol. 2013;20(11):3582–90.
30. Chen EQ, Zhou TY, Liu L, Liu C, Lei M, Tang H. A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: the 2-year results of a prospective study. Hepat Mon. 2011;11(1):27–31.
31. Hou JL, Yin YK, Xu DZ, Tan DM, Niu JQ, Zhou XQ, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47(2):447–54.
32. Xu DZ, Cai HD, Ma XY, Li YQ, Lu XZ, Yu HY, et al. Comparative analysis of the efficacies of entecavir capsules and lamivudine in chronic hepatitis B patients. Chin J Hepatol. 2013;21(12):886–90.
33. Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM, et al. Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients. Chin J Hepatol. 2009;17(12):881–6.
34. Jia JD, Hou JL, Yin YK, Tan DM, Xu DZ, Niu JQ, et al. Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatology. 2014;8:72–82.
35. Jia JD, Hou JL, Yin YK, Xu DZ, Tan DM, Niu JQ, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in Chinese chronic hepatitis B patients. Hepatol Int. 2009;3:43–4.
36. Ren H, Wang YM, Thongsawat S, Wan MB, Hou JL, Gane E, et al. Telbivudine induced HBeAg seroconversion in chronic hepatitis B (CHB) patients in durable during 2 years off-treatment follow-up. Hepatol Int. 2010;4:145–6.
37. Xu JH, Yu YY, Si CW, Ceng Z, Li J, Mao Q, et al. Analysis of a randomized, double-blind, double-dummy, controlled, multicenter study confirmed the similar therapeutic efficacies of entecavir maleate and entecavir for treatment of HBeAg-positive chronic hepatitis B. Chin J Hepatol. 2013;21(12):881–5.
38. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol. 2007;13(31):4264–7.
39. Du QW, Ding JG, Sun QF, Hong L, Cai FJ, Zhou QQ, et al. Combination lamivudine and adefovir versus entecavir for the treatment of naive chronic hepatitis B patients: a pilot study. Med Sci Monit. 2013;19:751–6.
40. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL, et al. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264–71.
41. National Bureau of Statistics of China. Census Data. 2010. http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm. Accessed Sep 2014.
42. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology. 2008;134(2):405–15.
43. Guo Y. Completing the policy of drug pricing. Chin Pharma Aff. 2009;22:2–3.
44. Beijing Municipal Commission of Development and Reform. Available from: http://service2.bjpc.gov.cn/bjpc/mediprice/WesternMedicine_qry.jsp. Accessed Sep 2014.
45. Hu M, Chen W. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health. 2009;12(Suppl 3):S89–92.
46. Gao Q. Economic analysis for liver and renal transplant in a transplant center. In: China Master's Theses Full-Text Database. 2007. http://www.cnki.net. Accessed Sept 2014.
47. Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11(3):527–38.
48. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14(4):339–47.
49. Kowdley KV. The cost of managing chronic hepatitis B infection: a global perspective. J Clin Gastroenterol. 2004;38(10 Suppl 3):S132–3.
50. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. 2009;51(4):640–6.
51. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2008;26(11):937–49.
52. Almeida AM, Silva AL, Brandao CM, Cherchiglia ML, Andrade EI, Araujo DOG, et al. Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B. Rev Saude Publica. 2012;46(6):942–9.
53. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86.